PwPepwise

Triptorelin

Sex & Libido

a.k.a. Trelstar · Decapeptyl

Long-acting GnRH analog

Triptorelin is a synthetic hormone analogue that mimics the body's natural gonadotropin-releasing hormone (GnRH), a chemical messenger.

§Dosing at a glance

5 protocols · from the research
What it's forDoseHow oftenHowFor how long
Breast Cancer — Ovarian Function Suppression (Adjuvant)3.75 mgEvery 4 wksIntramuscularInjected into a muscle.5 yrs
Prostate Cancer — Androgen Deprivation3.75 mg3× dailyOralTaken by mouth.9 mos
Assisted Reproduction (IVF — Long Protocol, LH Surge Prevention)0.1 mgDailySubcutaneousInjected just under the skin, into the fat layer.—
IVF — Oocyte Maturation Trigger (Antagonist Protocol)0.2 mg———
Endometriosis (Post-surgical Consolidation)3.75 mgEvery 4 wks—16 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Triptorelin is a synthetic hormone analogue that mimics the body's natural gonadotropin-releasing hormone (GnRH), a chemical messenger that controls the production of sex hormones such as estrogen and testosterone. When administered continuously, it effectively shuts down the hormonal signaling axis, dramatically lowering estrogen in women and testosterone in men. This property makes it a versatile tool across several medical conditions driven by sex hormones.

In women with hormone-sensitive breast cancer, triptorelin reduces disease recurrence when used as ovarian suppression alongside aromatase inhibitors or tamoxifen1,4. It also preserves ovarian function during chemotherapy, reducing the likelihood of early menopause2,10. In assisted reproduction, triptorelin prevents premature ovulation during IVF cycles, improving egg and embryo yields5,9. In men with advanced prostate cancer, triptorelin achieves and maintains castrate testosterone levels comparable to surgical castration12,14. It is also used to treat endometriosis, where it reduces disease burden comparably to oral alternatives20. Across these indications, triptorelin is generally well tolerated, with the most commonly reported effects being those expected from sex hormone suppression — including hot flashes and changes in bone density13,15.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Triptorelin ([D-Trp6]-LHRH) is a synthetic decapeptide analogue of endogenous gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). Its structure differs from native GnRH by a single amino acid substitution at position 6 — a D-tryptophan residue replacing the native glycine — which confers resistance to enzymatic degradation and substantially increases receptor binding affinity and biological half-life compared to the endogenous ligand.

Triptorelin acts as a potent agonist at pituitary GnRH receptors. Upon initial administration, it produces a transient stimulatory effect, triggering a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which transiently elevates gonadal steroid production. This initial flare is physiologically relevant and has been exploited therapeutically — for example, a single bolus dose of 0.2 mg SC effectively triggers the endogenous LH and FSH surges required for final oocyte maturation in IVF cycles19, with LH peaks observed at 4 hours and FSH peaks at 8 hours post-injection. The co-induced FSH surge is a distinguishing feature compared to hCG triggering, potentially conferring benefits for oocyte quality and corpus luteum formation19.

With continuous or depot administration, sustained GnRH receptor occupancy leads to receptor downregulation and desensitization through internalization and uncoupling of post-receptor signaling pathways. The pituitary becomes refractory to GnRH stimulation, leading to profound suppression of LH and FSH secretion and, consequently, dramatic reductions in gonadal steroid output. In women, continuous triptorelin administration (3.75 mg monthly) achieves median reductions of ≥95% in estradiol (E2), estrone (E1), and estrone sulfate (E1S) from baseline, reaching levels consistent with postmenopause11. In men, monthly injections of triptorelin pamoate 3.75 mg achieve castrate testosterone levels (≤1.735 nmol/L) in 91.2% of patients by day 29 and 97.7% by day 5712. The depth and consistency of hormonal suppression are the pharmacodynamic basis for triptorelin's utility in hormone-sensitive malignancies and endometriosis.

A clinically important pharmacodynamic nuance is that the degree of estrogen suppression achieved with monthly triptorelin is not uniform across patients. Approximately 17–25% of premenopausal women on exemestane plus monthly triptorelin fail to achieve E2 suppression below the 2.72 pg/mL threshold, with higher BMI, absence of prior chemotherapy, and lower baseline gonadotropins identified as independent predictors of suboptimal suppression11. This variability has implications for treatment optimization in aromatase inhibitor-based regimens and highlights that pharmacodynamic monitoring may be warranted in certain patient subgroups. The pharmacokinetics of depot triptorelin formulations are characterized by slow release from the injection site, sustaining therapeutic plasma concentrations over 28-day dosing intervals, making compliance-friendly monthly administration feasible across oncological, reproductive, and gynecological indications.

§04Evidence & efficacy

Evidence base
340Studies
217Human
9Animal

Triptorelin demonstrates well-established efficacy across several hormone-dependent conditions, with the strength of evidence varying by indication.

Adjuvant Breast Cancer — Ovarian Suppression:
Exemestane plus triptorelin-based ovarian suppression improves 5-year disease-free survival compared to tamoxifen plus ovarian suppression (91.1% vs. 87.3%; HR 0.72, P<0.001) and reduces breast cancer recurrence (HR 0.66, P<0.001) in premenopausal women with hormone receptor-positive early breast cancer1. A patient-level meta-analysis of 7,030 women confirms that aromatase inhibitors combined with ovarian suppression reduce overall breast cancer recurrence (RR 0.79, p=0.0005) and distant recurrence (RR 0.83, p=0.018) compared to tamoxifen plus ovarian suppression4. At 9.2-year follow-up, both letrozole plus triptorelin (HR 0.69, p=0.030) and zoledronic acid plus letrozole plus triptorelin (HR 0.58, p=0.002) significantly improve disease-free survival versus tamoxifen plus triptorelin8. Zoledronic acid plus letrozole plus triptorelin achieves a 5-year DFS of 93.3% compared to 85.4% for tamoxifen plus triptorelin (HR 0.52, P=0.003)6.

Ovarian Protection During Chemotherapy:
Triptorelin co-administration with chemotherapy reduces chemotherapy-induced early menopause from 25.9% to 8.9% (OR 0.28, P<0.001) in premenopausal breast cancer patients2. Long-term follow-up confirms higher 5-year cumulative menstrual resumption with triptorelin (72.6% vs. 64.0%; HR 1.48, P=0.006)10. In lymphoma patients, however, triptorelin does not significantly reduce premature ovarian failure (OR 0.702, P=0.651), and this benefit does not extend to that population17.

Prostate Cancer:
Triptorelin achieves castrate testosterone levels equivalent to leuprolide by day 57, maintaining castration in 98.8% of patients through 9 months12. Combined short-term triptorelin plus flutamide added to 80 Gy radiotherapy significantly improves 5-year disease-free survival (84% vs. 76%, HR 0.64) and reduces biochemical failure (HR 0.45)15. Triptorelin combined with flutamide demonstrates equivalent overall survival to parenteral estrogen therapy in advanced prostate cancer14.

Assisted Reproduction (IVF):
Triptorelin prevents premature LH surges in 100% of patients across all tested doses (vs. 23% surge rate with placebo), with the 50 mcg/day dose optimizing oocyte and embryo yield5. Ongoing pregnancy rates with triptorelin in long protocols are comparable to GnRH antagonist protocols (33.9% vs. 31.0%)9, though GnRH agonist triggering in antagonist cycles with standard luteal support produces substantially lower ongoing pregnancy rates18.

Endometriosis:
Triptorelin 3.75 mg every 4 weeks for 16 weeks post-laparoscopy reduces rAFS scores comparably to oral dienogest, with no statistically significant difference in efficacy between regimens20.

§05Safety

Triptorelin's safety profile is well characterized across a broad patient population and multiple indications, with the adverse effect spectrum largely predictable from its mechanism of sex hormone suppression.

Breast Cancer Settings:
In adjuvant breast cancer trials, grade 3 or 4 adverse events occurred in approximately 30% of patients receiving exemestane plus ovarian suppression and 29% receiving tamoxifen plus ovarian suppression, with profiles described as consistent with postmenopausal hormonal status1. Exemestane plus triptorelin was associated with persistent vaginal dryness, loss of sexual interest, arousal difficulties, and increased bone and joint pain, while tamoxifen plus triptorelin was associated with more hot flashes and sweating3. Aromatase inhibitor-based ovarian suppression is associated with significantly more bone fractures compared to tamoxifen-based regimens (6.4% vs. 5.1%)4. In the HOBOE trial, grade 3–4 adverse events were more frequent with the zoledronic acid plus letrozole plus triptorelin combination (9.1%) versus tamoxifen plus triptorelin (4.2%), with treatment discontinuation rates notably higher in the combination arm (16.6% vs. 7.3%)6.

IVF Settings:
Local skin reactions at the injection site occurred in approximately 24% of patients on the triptorelin long protocol, roughly twice the rate observed with GnRH antagonist protocols9. When used as a trigger in GnRH antagonist cycles with standard progesterone and estradiol luteal support, triptorelin was associated with substantially reduced ongoing pregnancy rates, indicating clinically significant luteal phase insufficiency in that specific protocol18.

Prostate Cancer Settings:
Hot flashes are a major tolerability concern with triptorelin-based androgen deprivation; the incidence reached 74.3% when triptorelin was combined with flutamide, compared to 30.1% with parenteral estrogen, with none of the androgen ablation patients achieving complete hot flash resolution13. Short-term ADT combining triptorelin with flutamide prior to and during radiotherapy was well tolerated, with no significant increase in acute or late gastrointestinal or genitourinary toxicity15. Cardiovascular mortality with triptorelin-based total androgen ablation was low (3.1%) and comparable to parenteral estrogen therapy14.

Ovarian Protection in Chemotherapy:
Triptorelin co-administration with chemotherapy did not significantly worsen disease-free survival (HR 1.17, P=0.52), supporting its oncologic safety in the breast cancer chemotherapy setting10. In lymphoma patients, triptorelin co-administration during chemotherapy did not demonstrate significant adverse outcomes beyond those attributable to the disease and its treatment17.

Estrogen Suppression Adequacy:
A clinically relevant safety-related finding is that 17–25% of patients on monthly triptorelin plus exemestane failed to achieve adequate estrogen suppression (E2 below 2.72 pg/mL) at various time points, with higher BMI, absence of prior chemotherapy, and lower baseline gonadotropins identified as risk factors for inadequate suppression11.

§06History

Triptorelin was developed in the late 1970s and early 1980s as part of a broader scientific effort to engineer stable, high-affinity analogues of the naturally occurring decapeptide GnRH (gonadotropin-releasing hormone), first isolated and sequenced by Andrew Schally and Roger Guillemin — work that earned them the 1977 Nobel Prize in Physiology or Medicine. The strategic substitution of D-tryptophan at position 6 of the native GnRH sequence yielded triptorelin, conferring metabolic stability, enhanced receptor affinity, and prolonged biological activity.

Early clinical development in the 1980s established triptorelin's utility in prostate cancer, leveraging the paradox that continuous GnRH receptor stimulation produces pituitary desensitization and downstream testosterone suppression — a form of reversible medical castration. Regulatory approval for advanced prostate cancer followed in several jurisdictions through the 1990s. Comparative RCT evidence through the early 2000s confirmed triptorelin's equivalence to surgical castration and to leuprolide in maintaining castrate testosterone levels over nine months12,14.

The reproductive medicine applications of triptorelin were pioneered through the 1990s and 2000s. Its role in IVF long protocols — suppressing premature LH surges during controlled ovarian stimulation — was validated in dose-finding RCTs5 and comparative trials against GnRH antagonists9,16. Triptorelin's role in breast cancer expanded significantly through the 2000s and 2010s via landmark trials including SOFT and TEXT1,3,11 and the GIM study2,10, establishing it as the preferred ovarian suppression agent in premenopausal adjuvant breast cancer management. The HOBOE trial further refined its use in combination with aromatase inhibitors and bisphosphonates6,8. Triptorelin is currently approved across multiple indications including prostate cancer, breast cancer, endometriosis, precocious puberty, and as an adjunct in assisted reproduction.

§07References